3Helix CHP Indication: Subretinal Fibrosis (nAMD)
Image Active Subretinal Fibrosis with CHPs
Introduction
3Helix Collagen Hybridizing Peptides (CHPs) are short peptides that selectively target damaged and remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science tools.
Summary
Subretinal Fibrosis (nAMD) Indication: Visualize active collagen remodeling in subretinal fibrosis, in vitro and in vivo, using CHPs to monitor disease activity and assess therapeutic efficacy.
Indication Note
Collagen Hybridizing Peptides can directly monitor active fibrosis dynamics in vivo.
Subretinal fibrosis is a critical driver of irreversible vision loss in neovascular Age-related Macular Degeneration (nAMD). Characterizing the dynamics of this fibrotic process, particularly distinguishing active collagen remodeling from scar tissue in vivo, is essential for developing and evaluating effective treatments. But this remains a major challenge. Current ophthalmic imaging lacks specific molecular probes to directly visualize active fibrosis in the back of the eye.
CHPs selectively target and visualize collagen damage resulting from fibrosis, allowing researchers to:
- Directly image and map active subretinal fibrosis in vivo within relevant preclinical models (Laser-CNV, JR5558) correlating CHP signal intensity with histological fibrosis markers and disease activity.
- Monitor disease activity dynamically by differentiating between active, progressing fibrosis (indicated by higher CHP binding) and stable or regressing scars (lower CHP binding) non-invasively over time.
-
Quantify changes in collagen remodeling in response to therapeutic interventions, providing a direct molecular readout to assess the efficacy of antifibrotic treatments targeting Subretinal Fibrosis.
Ilex Life Sciences LLC is an authorized distributor of CHP products manufactured by 3Helix, Inc.